Drug Profile
Cenplacel-L - Celularity
Alternative Names: PDA-001; PDAC cells - Celgene Cellular Therapeutics; Placental-derived adherent cells intravenousLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Celgene Cellular Therapeutics
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Crohn's disease
- No development reported Amyotrophic lateral sclerosis; Cancer; Graft-versus-host disease; Haematological disorders; Multiple sclerosis; Neuropathic pain; Rheumatoid arthritis; Ulcerative colitis
- Discontinued Pulmonary sarcoidosis; Stroke